Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients-Reference-Cited by-同舟云学术

Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients

Published:2016-06 Issue:6 Volume:24 Page:1100-1105
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Gil-Farina Irene,Fronza Raffaele,Kaeppel Christine,Lopez-Franco Esperanza,Ferreira Valerie,D'Avola Delia,Benito Alberto,Prieto Jesus,Petry Harald,Gonzalez-Aseguinolaza Gloria,Schmidt Manfred

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference35 articles.

1. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs;Haurigot;Mol Ther,2010

2. Safety and efficacy of gene transfer for Leber's congenital amaurosis;Maguire;N Engl J Med,2008

3. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration;Simonelli;Mol Ther,2010

4. Integration of adeno-associated virus (AAV) and recombinant AAV vectors;McCarty;Annu Rev Genet,2004

5. Genome engineering using adeno-associated virus: basic and clinical research applications;Gaj;Mol Ther,2016

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice;Molecular Therapy - Methods & Clinical Development;2024-09

2. Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article;Human Gene Therapy;2024-08-01

3. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

4. Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer;Blood;2024-06-06

5. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies;Mutation Research - Genetic Toxicology and Environmental Mutagenesis;2024-05